News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
BaFin Review Concerns Recognition of Pentixapharm Spin-off in 2024 Consolidated Financial Statements. Potential Income from Discontinued Operations Without Impact on Operating Key Figures.
BaFin reviews Eckert & Ziegler SE 2024 financial statements concerning Pentixapharm spin-off impact without affecting operating key figures. Close communication with BaFin ongoing -
-
-
-